摘要
多发性骨髓瘤(multiple myeloma,MM)是一种高度异质性恶性浆细胞疾病。蛋白酶体抑制剂(proteasome inhibitors,PIs)是治疗MM的一线药物,硼替佐米、伊莎佐米和卡非佐米也广泛应用于MM的治疗中,marizomib、奥泼佐米和KZR-616正在临床试验中。然而,PIs在MM中仍存在耐药问题。目前有关PIs对MM的耐药机制包括泛素-蛋白酶体通路、自噬溶酶体通路、内质网应激通路、细胞促存活信号通路,以及外泌体介导耐药和骨髓微坏境介导耐药。
Multiple myeloma(MM)is a highly heterogeneous malignant plasma cell disease.Proteasome inhibitors(PIs)are the first line of medicine for MM.Bortezomib,ixazomib,and carfilzomib are also widely used for MM.Marizomib,oprozomib,and KZR-616 are in clinical trials.However,the drug resistance of PIs in MM is still a problem.The mechanisms for PIs resistance to MM include ubiquitin-proteasome pathway,autophagy lysosome pathway,endoplasmic reticulum stress pathway,cell survival signal pathway,exosome-mediated resistance,and bone marrow microenvironment-mediated resistance.
作者
吴姣
刘竞
WU Jiao;LIU Jing(Department of Hematology,Loudi Gereral Hospital,Loudi Hunan 417000;Department of Hematology,Third Xiangya Hospital,Central South University,Changsha 410013,China)
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2021年第8期900-908,共9页
Journal of Central South University ：Medical Science
关键词
多发性骨髓瘤
蛋白酶体抑制剂
耐药
multiple myeloma
proteasome inhibitor
drug resistance
